Prostate cancer surgery in high risk patients - experimental?

Poster Session 60

Sunday 18 March
15:45 - 17:15

Location: Blue Area, Room 3 (Level 0)
Chairs: X. Cathelineau, Paris (FR)
        M. Graefen, Hamburg (DE)
        H. Matsuyama, Ube (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

812
Identification of treatable high risk prostate cancer only by radical prostatectomy - who are good candidates for radical prostatectomy in high risk prostate cancer

By: Nagao K., Mori J., Shimizu K., Kawai Y., Inoue R., Yamamoto Y., Matsumoto H., Matsuyama H.
Graduate School of Medicine, Yamaguchi University, Dept. of Urology, Ube, Japan

813
The influence of tracer injection into the prostate for the detection of lymph node metastases in prostate cancer during robot assisted radical prostatectomy with sentinel node procedure: A phase II randomized comparison

By: Wit E., Kleinjan G., Donswijk M., Leeuwen Van F., Poel Van Der H.
The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Dept. of Urology, Amsterdam, Netherlands, The
Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Leiden, Netherlands, The
The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Dept. of Nuclear Medicine, Amsterdam, Netherlands, The

814
Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution

By: Fujita N., Koie T., Tobisawa Y., Yoneyama T., Yamamoto H., Imai A., Hatakeyama S., Yoneyama T., Hashimoto Y., Ohyama C.
Hirosaki university, Dept. of Urology, Hirosaki, Japan

815
Neoadjuvant chemo-hormonal therapy combined with radical prostatectomy and extend PNLD for very high risk locally advanced prostate cancer: A 3-arms retrospective comparative study

By: Pan J., Chenfei C., Yinjie Z., Xiaoguang S., Jianjun S., Fan X., Yanqing W., Baijun D., Wei X.
Ren Ji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Dept. of Urology, Shanghai, China
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 816     | Androgen deprivation therapy should not be used as monotherapy in high or very high risk localized prostate cancer | Choi S.Y., Ryu J., Lee J., Lee W., Chae H.K., Choi W., Kyung Y.S., Park S., Moon K.H., You D., Jeong I.G., Hong J.H., Ahn H., Kim C., Han J.H.  
1 Asan Medical Center, Dept. of Urology, Seoul, Korea, South,  
2 Ulsan University Hospital, Dept. of Urology, Ulsan, Korea, South |
| 817     | Neoadjuvant docetaxel plus goserelin in patients with very-high risk, locally advanced prostate cancer: Initial results from a randomized study | Zhang H.L., Zhu Y., Dai B., Ye D.W.  
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China |
| 818     | Multi-institutional prospective study comparing oncological outcomes between radical prostatectomy with extended pelvic lymph node dissection versus radiotherapy and long-term adjuvant androgen deprivation therapy for high risk localized prostate cancer | Ahallal Y., Escande A., Zanettini L.F.S., Colau A., Bossi A., Guillonneau B.  
1 Diaconesses-Croix St Simon Hospital, Dept. of Urology, Paris, France,  
2 Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France |
1 Asan Medical Center, Dept. of Urology, Seoul, Korea, South,  
2 Ulsan University Hospital, Dept. of Urology, Ulsan, Korea, South |
| 820     | Long-term oncological outcomes after radical prostatectomy and extended pelvic lymph node dissection in high-risk prostate cancer: Comparing last decade to previous 20 years | Rubio Briones J., Ramirez Backhaus M., Gómez-Ferrer A., Mir Maresme C., Domínguez Escrig J., Collado Serra A., Solsona E., Mascarós J.M., Casanova J.  
Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain |
| 821     | Stage-migration and survival of lymph node positive prostate cancer patients: A comprehensive trend analyses of surgically treated men over the last two decades | Bandini M., Dell'Oglio P., Gandaglia G., Fossati N., Stabile A., Zaffuto E., Bianchi M., Bravi C.A., Mazzone E., Preissler F., Soligo M., Shariat S., Montironi R., Karakiewicz P., Karnes J., Graefen M., Tilki D., Montorsi F. |
Contemporary trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients

By: Bandini M.¹, Preisser F.², Nazzani S.³, Marchioni M.⁴, Tian Z.⁵, Smith A.⁶, Bondarenko H.⁵, Gallina A.¹, Abdollah F.⁷, Shariat S.⁸, Montorsi F.¹, Saad F.⁵, Tilki D.², Briganti A.⁹, Karakiewicz P.⁵

¹IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Urology/Urological Oncology, Milan, Italy, ²University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Dept. of Pathological Anatomy, Ancona, Italy, ⁶University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

Radical cystoprostatectomy in high risk prostate cancer. Is it worth it?

By: Kowalski F.¹, Wilamowski J.¹, Ostrowski A.¹, Adamowicz J.¹, Bryczkowski M.¹, Baranowski A.², Mikołajczak W.², Drewa T.¹

¹A.Jurasz University Hospital No.1, Dept. of Urology, Bydgoszcz, Poland, ²Nicolaus Copernicus Specialist Municipal Hospital, Dept. of Urology, Toruń, Poland

The role of primary surgery and external beam radiation therapy in the management of non-metastatic ductal prostate cancer: 20-year outcomes from a single institution experience

By: Francavilla S.¹, Triggiani L.², Palumbo C.¹, Bardoscia L.², Tellini R.¹, Buglione M.², Peroni A.¹, Antonelli A.¹, Magrini S.M.², Simeone C.¹

¹Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ²Spedali Civili Hospital, University of Brescia, Dept. of Radiation Oncology, Brescia, Italy

Zero PSA after RP: It is reasonable in selected N+ prostate cancer patients if a ePLND is performed

By: Ramírez Backhaus M.¹, Mir Maresma C.¹, Mascarós J.M.², Mamber A.¹, Gómez-Ferrer A.¹, Domínguez-Escrig J.L.¹, Casanova J.L.³, Iborra I.¹, Monróis J.L.¹, Collado Serra A.¹, Hernández J.¹, Spinetti G.¹, Calatrava Fons A.⁴, Rubio-Briones J.¹

¹IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Dept. of Urology/Urologic Oncology, Milan, Italy
Effect of extended pelvic lymph node dissection on oncologic outcomes in D’Amico intermediate- and high-risk radical prostatectomy patients


1University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, 2Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, 3IRCCS Ospedale San Raffaele, Unit of Urology/Division of Oncology, URI, Milan, Italy, 4Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium, 5Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, 6University College London Hospital, Dept. of Uro-oncology, London, United Kingdom, 7Henri Mondor Hospital, Assistance-Publique Hopitaux de Paris, Dept. of Urology, Creteil, France